skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel

Journal Article · · Journal of Virology
DOI:https://doi.org/10.1128/JVI.00754-15· OSTI ID:1213733
 [1];  [1];  [2];  [1]
  1. NYU School of Medicine, NY (United States)
  2. NYU School of Medicine, NY (United States); Veterans Affairs New York Harbor Healthcare System, New York, NY (United States)

The region consisting of the first and second variable regions (V1V2) of gp120 plays vital roles in the functioning of the HIV-1 envelope (Env). V1V2, which harbors multiple glycans and is highly sequence diverse, is located at the Env apex and stabilizes the trimeric gp120 spike on the virion surface. It shields V3 and the coreceptor binding sites in the prefusion state and exposes them upon CD4 binding. Data from the RV144 human HIV-1 vaccine trial suggested that antibody responses targeting the V1V2 region inversely correlated with the risk of infection; thus, understanding the antigenic structure of V1V2 can contribute to vaccine design. We have determined a crystal structure of a V1V2 scaffold molecule (V1V2ZM109-1FD6) in complex with 830A, a human monoclonal antibody that recognizes a V1V2 epitope overlapping the integrin-binding motif in V2. The structure revealed that V1V2 assumes a five-stranded beta barrel structure with the region of the integrin-binding site (amino acids [aa] 179 to 181) included in a “kink” followed by an extra beta strand. The complete barrel structure naturally presents the glycans on its outer surface and packs into its core conserved hydrophobic residues, including the Ile at position 181 which was highly correlated with vaccine efficacy in RV144. The epitope of monoclonal antibody 830A is discontinuous and composed of three segments: (i) Thr175, Tyr177, Leu179, and Asp180at the kink overlapping the integrin-binding site; (ii) Arg153and Val154in V1; and (iii) Ile194at the C terminus of V2. Here, this report thus provides the atomic details of the immunogenic “V2i epitope.”

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE Office of Science (SC), Basic Energy Sciences (BES); National Inst. of Health; National Cancer Inst.; National Inst. of General Medical Sciences
Grant/Contract Number:
AC02-06CH11357; AI100151; AI082274; AI084119; HL059725; Y1-CO-1020; Y1-GM-1104
OSTI ID:
1213733
Journal Information:
Journal of Virology, Vol. 89, Issue 15; ISSN 0022-538X
Publisher:
American Society for MicrobiologyCopyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 49 works
Citation information provided by
Web of Science

References (45)

Structure and immune recognition of trimeric pre-fusion HIV-1 Env journal October 2014
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens journal June 1998
Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2 journal July 2013
Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line journal October 2002
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 journal November 2011
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection journal February 2014
Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 journal May 2013
Structural specializations of α 4 β 7 , an integrin that mediates rolling adhesion journal January 2012
Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection journal November 2014
Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope journal August 2014
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial journal April 2012
Structure of a V3-Containing HIV-1 gp120 Core journal November 2005
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody journal June 1998
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 journal January 2013
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 journal September 2012
PHENIX : building new software for automated crystallographic structure determination journal October 2002
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer journal October 2013
Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals journal June 2012
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer journal October 2013
Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies journal May 2011
Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7 journal May 2012
XDS journal January 2010
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold journal September 2010
Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA journal July 2011
Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design journal July 2010
HIV-1 Envelope Subregion Length Variation during Disease Progression journal December 2010
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. journal January 1993
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. journal January 1987
Coot model-building tools for molecular graphics journal November 2004
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target journal September 2009
Quaternary Epitope Specificities of Anti-HIV-1 Neutralizing Antibodies Generated in Rhesus Macaques Infected by the Simian/Human Immunodeficiency Virus SHIVSF162P4 journal January 2010
Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial journal January 2013
Estimated Secondary Structure Propensities within V1/V2 Region of HIV gp120 Are an Important Global Antibody Neutralization Sensitivity Determinant journal April 2014
HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells journal February 2008
ICM?A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation journal May 1994
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. journal January 1994
A Twin-Cysteine Motif in the V2 Region of gp120 Is Associated with SIV Envelope Trimer Stabilization journal July 2013
Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles journal April 2005
Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope journal August 2014
Protein modules and signalling networks journal February 1995
Complete Nucleotide Sequences of Functional Clones of the AIDS Virus journal January 1987
Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV journal January 2014
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites journal December 2002
Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. journal June 1990
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997

Cited By (12)

Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations journal January 2018
The β20–β21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions journal October 2017
Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers journal April 2018
Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity journal October 2017
Opening dynamics of HIV-1 gp120 upon receptor binding is dictated by a key hydrophobic core journal January 2019
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant journal April 2018
Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant journal May 2017
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7 journal August 2018
Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions journal October 2018
Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials journal January 2018
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response journal September 2016
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design journal December 2015